WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326684

CAS#: 1352792-74-5

Description: Verinurad, also known as RDEA3170, is an organic anion transporter URAT1 (SLC22A12) inhibitor, is being developed by Ardea Biosciences (a subsidiary of AstraZeneca) for the treatment of gout and hyperuricaemia.

Price and Availability

Size Price Shipping out time Quantity
25mg USD 150 Same day
50mg USD 250 Same day
100mg USD 450 Same day
200mg USD 750 Same day
500mg USD 1150 Same day
1g USD 1650 Same day
2g USD 2650 Same day
5g USD 3850 Same day
Inquire bulk and customized quantity

Pricing updated 2021-01-25. Prices are subject to change without notice.

Verinurad, purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 326684
Name: Verinurad
CAS#: 1352792-74-5
Chemical Formula: C20H16N2O2S
Exact Mass: 348.0932
Molecular Weight: 348.42
Elemental Analysis: C, 68.95; H, 4.63; N, 8.04; O, 9.18; S, 9.20

Synonym: RDEA3170; RDEA-3170; RDEA 3170; Verinurad

IUPAC/Chemical Name: 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid


InChi Code: InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)

SMILES Code: CC(C)(SC1=C(C2=C3C=CC=CC3=C(C#N)C=C2)C=NC=C1)C(O)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Diaz-Torné C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015 Mar;27(2):164-9. doi: 10.1097/BOR.0000000000000146. Review. PubMed PMID: 25603039.